

VIII CONGRESSO NAZIONALE B&M

Quanto il peso corporeo influenza l'assorbimento della levodopa?

Dott.ssa Erica Cassani

- **PAZIENTE DI 42 ANNI**
- Parkinsonismo esordito nel marzo 2017 con tremore a riposo ingravescente all'emisoma sinistro e iposmia.
- Dal luglio 2017 compare anche disartria con balbuzie.
- Obesità di terzo grado (BMI 47 kg/m²).



Figure 1.

The table display variation of metabolic parameters, diet therapy and pharmacological therapy


<u>Year of visit</u>	2017			2018			
<u>Month of visit</u>	<u>October</u>	<u>January</u>	<u>February</u>	<u>March</u>	<u>April</u>	<u>June</u>	<u>August</u>
WEIGHT kg	138	138	129	126	122	116	109
Δ WEIGHT from 1st visit	-	-	-9 kg (-7 %)	-12 kg (-9 %)	-16 kg (-11.7 %)	-22 kg (-16 %)	-29 kg (-21 %)
BMI Kg/m² Δ Kg/m²	47	47	44.2 (-2.8)	42 (-5)	41 (-6)	39 (-9)	37.2 (-9.8)
	<u>Obesity III</u>	<u>Obesity III</u>	<u>Obesity III</u>	<u>Obesity III</u>	<u>Obesity III</u>	<u>Obesity II</u>	<u>Obesity II</u>
FM kg (BIA) Δ kg Δ %	-	66.8	-	-	57 (-9.8 kg) (-14.6 %)	-	49.5 (-17.3 kg) (-25.9 %)
DIET Kcal kjoule	1600 6690	1600 6690	1600 6690	1600 6690	1600 6690	1600 6690	1600 6690
LIRAGLUTIDE mg	-	1.2	1.8	1.2	1.2/1.8 On alternate <u>day</u>	1.2/1.8 On alternate <u>day</u>	1.2/1.8 On alternate <u>day</u>
CALORIMETRY	-	MB=2078 Kcal/die	-	-	-	-	-
LEVODOPA/ BENSERAZIDE mg	100+25 x 4	100+25 x 2 150+37.5 x 2	150+37.5 x 4	150+37.5 x 4	150+37.5 x 4	150+37.5 x 4	150+37.5 x 4
PRAMIPEXOLE RP	1 mg	1 mg	3 mg	3 mg	3 mg	2.2 mg	2.2 mg
SAFINAMIDE	-	-	-	-	-	-	50 mg
L-DOPA PHARMACOKINETICS	-	-	<u>done</u>	-	-	<u>done</u>	-

Peso Corporeo e Farmacocinetica della Levodopa

Case Report



Baseline 13/2/2018: 130 Kg

- Wearing-off a 2h circa
- Risposta test con L-Dopa -20%



Follow-up 01/06/2018: 116,5 Kg (-10,2%)

- Wearing-off a 2h 30' circa
- Risposta test con L-Dopa -70%






Δ Peso Corporeo e Farmacocinetica della Levodopa

Case Report

	13/02/2018	01/06/2018
AUC (µg/ml) x min	119	235
Cmax (µg/ml)	1,45	2,98
Tmax (min)	60	60

↑ 97% della Area Under the Curve (AUC)

↑ 105% del Cmax




Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial



Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson, Yazhou Li, Iciar Aviles-Olmos, Thomas T Warner, Patricia Limousin, Andrew J Lees, Nigel H Greig, Susan Tebbs, Thomas Foltynie

www.thelancet.com Published online August 3, 2017



	Baseline	12 weeks	24 weeks	36 weeks	48 weeks	Change (0-48 weeks)
Weight (kg)						
Exenatide	81.8 (16.6)	80.0 (16.3)	79.3 (16.5)	78.1 (15.9)	79.2 (16.1)	-2.6 (-4.0 to -1.2)
Placebo	80.8 (12.9)	80.1 (14.3)	80.2 (14.0)	79.5 (13.6)	80.2 (13.3)	-0.6 (-1.9 to 0.8)

VIII CONGRESSO NAZIONALE B&M

Grazie per l'attenzione